Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - artemether, quantity: 20 mg; lumefantrine, quantity: 120 mg - tablet, dispersible - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; crospovidone; saccharin sodium; hypromellose; magnesium stearate; polysorbate 80; colloidal anhydrous silica; flavour - riamet tablet is indicated for the treatment of acute, uncomplicated malaria due to plasmodium falciparum in adults, children and infants of 5kg and above. riamet dispersible tablet is indicated for the treatment of acute, uncomplicated malaria due to plasmodium falciparum in children and infants weighing between 5kg and less than 35kg.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - fexofenadine hydrochloride 120mg;   - tablet - 120 mg - active: fexofenadine hydrochloride 120mg   excipient: croscarmellose sodium lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry povidone purified talc purified water sodium laurilsulfate

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - etoricoxib, quantity: 120 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cipla etoricoxib is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - lumefantrine, quantity: 120 mg; artemether, quantity: 20 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; polysorbate 80; croscarmellose sodium; hypromellose - riamet tablet is indicated for the treatment of acute, uncomplicated malaria due to plasmodium falciparum in adults, children and infants of 5kg and above. riamet is indicated for the treatment of acute, uncomplicated malaria due to plasmodium falciparum in patients aged at least 12 years and weighing at least 35kg.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - fexofenadine hydrochloride, quantity: 120 mg - tablet, film coated - excipient ingredients: hypromellose; macrogol 400; titanium dioxide; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; povidone; colloidal anhydrous silica; pregelatinised maize starch; iron oxide yellow; iron oxide red - relief of symptoms associated with seasonal allergic rhinitis for adults and children aged 12 years and over.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - etoricoxib - film coated tablets - etoricoxib 120 mg - etoricoxib - etoricoxib - arcoxia 120 mg tablets are indicated for the symptomatic relief of the pain and signs of inflammation associated with acute gouty arthritis.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - etoricoxib, quantity: 120 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; carnauba wax; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; indigo carmine; triacetin; iron oxide yellow - arcoxia is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a. menarini farmaceutica internazionale srl - febuxostat - tablet - 120mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: triethyl citrate; iron oxide red; magnesium stearate; sodium starch glycollate type a; titanium dioxide; methacrylic acid copolymer; purified talc; hypromellose; silicon dioxide; macrogol 6000; carmellose sodium; microcrystalline cellulose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

air liquide healthcare pty ltd - air, quantity: 100 % v/v - gas, medicinal - excipient ingredients: - for normal respiration. in anaesthetic equipment as a carrier gas during surgery. for nebulisation of inhaled drugs when oxygen supplementation is not required.